Orexo AB (publ)
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company i… Read more
Orexo AB (publ) (ORXOF) - Total Liabilities
Latest total liabilities as of December 2025: $812.20 Million USD
Based on the latest financial reports, Orexo AB (publ) (ORXOF) has total liabilities worth $812.20 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Orexo AB (publ) - Total Liabilities Trend (2015–2025)
This chart illustrates how Orexo AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Orexo AB (publ) Competitors by Total Liabilities
The table below lists competitors of Orexo AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dhunseri Investments Limited
NSE:DHUNINV
|
India | ₹11.35 Billion |
|
HAVRF
PINK:HAVRF
|
USA | $1.77 Million |
|
Carlos Casado
BA:CADO
|
Argentina | AR$17.44 Billion |
|
Chian Hsing Forging Industrial Co Ltd
TWO:4528
|
Taiwan | NT$1.46 Billion |
|
Genetec Technology Bhd
KLSE:0104
|
Malaysia | RM132.62 Million |
|
World Known MFG (Cayman) Limited
TW:4581
|
Taiwan | NT$1.20 Billion |
|
Cyan AG
XETRA:CYR
|
Germany | €3.63 Million |
|
Optivision Technology
TWO:3666
|
Taiwan | NT$387.67 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Orexo AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orexo AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orexo AB (publ) (2015–2025)
The table below shows the annual total liabilities of Orexo AB (publ) from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $812.20 Million | +12.63% |
| 2024-12-31 | $721.10 Million | -0.91% |
| 2023-12-31 | $727.70 Million | -20.48% |
| 2022-12-31 | $915.10 Million | -0.97% |
| 2021-12-31 | $924.10 Million | +37.03% |
| 2020-12-31 | $674.40 Million | -15.14% |
| 2019-12-31 | $794.70 Million | -1.96% |
| 2018-12-31 | $810.60 Million | +20.12% |
| 2017-12-31 | $674.80 Million | -4.76% |
| 2016-12-31 | $708.50 Million | -5.52% |
| 2015-12-31 | $749.90 Million | -- |